Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Real-world treatment patterns for HER2-amplified colorectal cancer

John Strickler, MD, Duke Cancer Institute, Durham, NC, comments on the how HER2-amplified colorectal cancer (CRC) is treated in real-world settings. Despite anti-HER2 therapies such as tucatinib and trastuzumab in current treatment guidelines, only approximately half of patients with HER2-amplified CRC are receiving the recommended treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.